Streicher K - Search Results

1

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.

Chia YL, Tummala R, Mai TH, Rouse T, Streicher K, White WI, Morand EF, Furie RA. Chia YL, et al. Among authors: streicher k. J Clin Pharmacol. 2022 Sep;62(9):1094-1105. doi: 10.1002/jcph.2054. Epub 2022 May 21. J Clin Pharmacol. 2022. PMID: 35352835 Free PMC article.

2

Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody.

Wang B, Higgs BW, Chang L, Vainshtein I, Liu Z, Streicher K, Liang M, White WI, Yoo S, Richman L, Jallal B, Roskos L, Yao Y. Wang B, et al. Among authors: streicher k. Clin Pharmacol Ther. 2013 Jun;93(6):483-92. doi: 10.1038/clpt.2013.35. Epub 2013 Feb 14. Clin Pharmacol Ther. 2013. PMID: 23511714 Clinical Trial.

3

Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.

Streicher K, Sridhar S, Kuziora M, Morehouse CA, Higgs BW, Sebastian Y, Groves CJ, Pilataxi F, Brohawn PZ, Herbst R, Ranade K. Streicher K, et al. Arthritis Rheumatol. 2018 Dec;70(12):2087-2095. doi: 10.1002/art.40656. Epub 2018 Oct 22. Arthritis Rheumatol. 2018. PMID: 29956883 Clinical Trial.

4

Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures.

Brohawn PZ, Streicher K, Higgs BW, Morehouse C, Liu H, Illei G, Ranade K. Brohawn PZ, et al. Among authors: streicher k. Lupus. 2019 Nov;28(13):1524-1533. doi: 10.1177/0961203319885447. Epub 2019 Oct 29. Lupus. 2019. PMID: 31660791 Clinical Trial.

5

Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus.

Smith MA, Chiang CC, Zerrouki K, Rahman S, White WI, Streicher K, Rees WA, Schiffenbauer A, Rider LG, Miller FW, Manna Z, Hasni S, Kaplan MJ, Siegel R, Sinibaldi D, Sanjuan MA, Casey KA. Smith MA, et al. Among authors: streicher k. Sci Rep. 2020 Mar 10;10(1):4462. doi: 10.1038/s41598-020-60563-9. Sci Rep. 2020. PMID: 32157125 Free PMC article.

6

The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.

Ramaswamy M, Tummala R, Streicher K, Nogueira da Costa A, Brohawn PZ. Ramaswamy M, et al. Among authors: streicher k. Int J Mol Sci. 2021 Oct 19;22(20):11286. doi: 10.3390/ijms222011286. Int J Mol Sci. 2021. PMID: 34681945 Free PMC article. Review.

7

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.

Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Vital EM, et al. Among authors: streicher k. Ann Rheum Dis. 2022 Jul;81(7):951-961. doi: 10.1136/annrheumdis-2021-221425. Epub 2022 Mar 25. Ann Rheum Dis. 2022. PMID: 35338035 Free PMC article. Clinical Trial.

8

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma.

Cheng L, Creasy T, Pilataxi F, Greenlees L, Vence L, Sridhar S, Streicher K. Cheng L, et al. Among authors: streicher k. Cancer Immunol Immunother. 2022 May;71(5):1167-1181. doi: 10.1007/s00262-021-03065-5. Epub 2021 Oct 8. Cancer Immunol Immunother. 2022. PMID: 34623465 Free PMC article.

9

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E. Brightling CE, et al. Among authors: streicher k. Lancet Respir Med. 2015 Sep;3(9):692-701. doi: 10.1016/S2213-2600(15)00197-6. Epub 2015 Jul 28. Lancet Respir Med. 2015. PMID: 26231288 Clinical Trial.

10

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.

Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, Kim K, Campos JAS, Arends RH, Brodek BH, Brooks D, Garbes P, Jimenez J, Koh GCKW, Padilla KW, Streicher K, Viani RM, Alagappan V, Pangalos MN, Esser MT; TACKLE study group. Montgomery H, et al. Among authors: streicher k. Lancet Respir Med. 2022 Oct;10(10):985-996. doi: 10.1016/S2213-2600(22)00180-1. Epub 2022 Jun 7. Lancet Respir Med. 2022. PMID: 35688164 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters